For patients who have completed up-front docetaxel for metastatic castration-sensitive prostate cancer, should they proceed to abiraterone before the development of castration resistance?

There is data for upfront triplet therapy currently in high-volume HSPC. The triplet therapy consists of ADT + docetaxel x 6 cycles + either darolutamide or abiraterone. Given that this patient has already completed a course of docetaxel, holding off on adding ARSI therapy until the first signs of P...